LONDON, Sept 21: Wegovy-maker Novo Nordisk's CEO Mike Doustdar will face pressure on Monday to set out his strategy for competing with US rival Eli Lilly and how he plans to boost the company's growth beyond the blockbuster weight-loss drug.
Novo rode a wave of demand after launching Wegovy in 2021 which helped it become Europe's most valuable listed firm in 2023 with a market capitalisation of more than $600 billion.